Securities Code: 301584 Securities Abbreviation: Jinfu Xinxin Announcement No.: 2026-010 Shanghai Jinfu Xinxin Medical Technology Group Co., Ltd. Announcement on Progress of Guarantees for Subsidiaries The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and have no false records, misleading statements, or material omissions.
Special Risk Warning: Shanghai Jinfu Xinxin Medical Technology Group Co., Ltd. (hereinafter referred to as the "Company") and its holding subsidiaries have provided guarantees totaling more than 100% of the Company's net assets as per the latest audited figures. Guarantees for holding subsidiaries with a liability-to-asset ratio exceeding 70% are projected to exceed 50% of the Company's net assets as per the latest audited figures. The aforementioned guarantees are all for subsidiaries within the scope of the Company's consolidated financial statements. The financial risks are within the Company's controllable range. Investors are advised to pay close attention to the guarantee risks.
I. Overview of External Guarantees In accordance with the Company's business development strategy, capital budget, and capital security needs, from the date of the Company's 2024 Annual Shareholders' Meeting to the date of the 2025 Annual Shareholders' Meeting, the Company and its holding subsidiaries plan to apply for a comprehensive credit line of no more than RMB 15 billion from various banks and financial institutions. This matter has been deliberated and approved by the Company's 2024 Annual Shareholders' Meeting and the 2025 First Extraordinary Shareholders' Meeting. Given that some of the financing entities within this credit line are the Company's holding subsidiaries, to ensure the smooth application for credit lines by the subsidiaries, from the date of the Company's 2024 Annual Shareholders' Meeting to the date of the 2025 Annual Shareholders' Meeting, the Company expects to provide guarantees totaling no more than RMB 7 billion for comprehensive credit lines applied for by subsidiaries within the consolidated financial statements scope or for related business activities. Among these, the guarantee limit for subsidiaries within the consolidated financial statements scope with a liability-to-asset ratio exceeding 70% is RMB 6.5 billion, and the guarantee limit for subsidiaries within the consolidated financial statements scope with a liability-to-asset ratio below 70% is RMB 0.5 billion. Within the total guarantee limit, subsidiaries can adjust guarantee limits among themselves. If a subsidiary (recipient of the limit) has a liability-to-asset ratio exceeding 70%, the required adjusted guarantee limit can only be obtained from other subsidiaries (providers of the limit) that also have a liability-to-asset ratio exceeding 70%. The Company held its Third Board of Directors' Eighth Meeting and Third Supervisory Board's Seventh Meeting on March 28, 2025, and convened the 2024 Annual Shareholders' Meeting on April 18, 2025, which deliberated and approved the "Proposal on Guarantees for Wholly-owned and Holding Subsidiaries in 2025." Prior to the 2025 Annual Shareholders' Meeting, the Company plans to provide guarantees totaling no more than RMB 7 billion for comprehensive credit lines applied for by subsidiaries within the consolidated financial statements scope or for related business activities. The types of businesses covered by the comprehensive credit line guarantees include, but are not limited to, bank financing, bank acceptance bills, supply chain finance, and leasing financing. The specific guarantee terms are subject to the contracts signed with each financial institution. Within the aforementioned guarantee limit, the Company's management may adjust the guarantee amounts between subsidiaries based on actual needs and may also provide guarantees for newly established subsidiaries. For detailed information, please refer to the announcement disclosed by the Company on Juchao Information Network (http://www.cninfo.com.cn) on October 30, 2025.